[4-(hydroxymethy)pheny]-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranoside) | 148579-46-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [4-(hydroxymethy)pheny]-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranoside)
• 英文别名: 4-hydroxymethylphenyl 2,3,4,6-tetra-O-acetyl-α-D-galactopyranoside；4-Hydroxymethylphenyl 2,3,4,6-tetra-O-acetyl-alpha-D-galactopyranoside；[(2R,3S,4S,5R,6R)-3,4,5-triacetyloxy-6-[4-(hydroxymethyl)phenoxy]oxan-2-yl]methyl acetate
• CAS: 148579-46-8
• 化学式: C₂₁H₂₆O₁₁
• 分子量: 454.431
• InChiKey: HGUDVDQXCUHOED-IFLJBQAJSA-N

物化性质

• 沸点：
  551.4±50.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  32
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  144
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  [4-(hydroxymethy)pheny]-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranoside) 生成 2,5-Dioxopyrrolidin-1-yl 4-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)benzyl carbonate
  参考文献：
  名称：

  Glycosylated prodrugs, their method of preparation and their uses

  摘要：

  糖基化前药、其制备方法以及其与肿瘤特异性免疫酶偶联物一起用于治疗癌症的用途被描述。这些蒽环类前药的化学式为(I)。

  公开号：

  US05561119A1
• 作为产物：
  描述：

  2,3,4,6-四乙酰氧基-alpha-D-吡喃糖溴化物 在 sodium tetrahydroborate 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 [4-(hydroxymethy)pheny]-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranoside)
  参考文献：
  名称：

  用于精确跟踪衰老的近红外比率荧光探针：细胞衰老途径中生物标志物的多维传感测定

  摘要：

  衰老是一个复杂的生理过程，可由多种因素引起，活性氧（ROS）引起的细胞损伤是主要触发因素之一。为了了解和解决与年龄相关的疾病，通过具有高灵敏度和准确性的生物标志物（包括衰老相关β-半乳糖苷酶（SA-β-gal））进行跟踪策略被认为是一种有前途的解决方案。然而，内源性β-gal积累不仅与衰老有关，还与其他生理过程有关。因此，需要额外的测定来进一步定义细胞衰老。在这项工作中，由于 β-gal 的作用，开发了一种用于精确监测衰老的精美荧光探针SA-HCy-1 ，特别是在高溶酶体 pH 条件（pH > 6.0）下以 SA-β-gal 和 HClO 作为靶标通常作为卵巢癌的生物标志物。因此，鉴于这三个维度，可以实现细胞衰老的精确跟踪，双荧光通道中的响应提供比率传感模式。通过皮肤光老化评估和细胞传代追踪，这一精心设计的策略已被证实适合生物应用，与商业 X-gal 试剂盒测量相比，其灵敏度显着提高。

  DOI：

  10.1039/d4sc00595c

文献信息

• A Novel Ratiometric Fluorescent Probe for Highly Sensitive and Selective Detection of β‐Galactosidase in Living Cells
  作者：Min Chen、Lixuan Mu、Xingxing Cao、Guangwei She、Wensheng Shi

  DOI：10.1002/cjoc.201800539

  日期：2019.4

  β‐Galactosidase, a glycoside hydrolase enzyme, has been proved to be an important biomarker of cell senescence and primary ovarian cancer. Effective detection of β‐galactosidase has attracted wide attention. Herein, one ratiometric fluorescent probe has been successfully synthesized for detecting the β‐galactosidase in living cells. The as‐prepared probe exhibits two emission peaks at 490 nm and 530 nm, respectively

  β-半乳糖苷酶（一种糖苷水解酶）已被证明是细胞衰老和原发性卵巢癌的重要生物标志物。有效检测β-半乳糖苷酶已引起广泛关注。本文成功地合成了一种比例荧光探针，用于检测活细胞中的β-半乳糖苷酶。所制备的探针分别在490 nm和530 nm处显示两个发射峰，并且可以利用这两个发射峰的荧光强度比率来监测β-半乳糖苷酶。因此，这种目前的比例荧光探针对于有效，灵敏和选择性地检测活细胞中的β-半乳糖苷酶非常有前途。
• [EN] EPOTHILONE ANALOGS FOR SITE SPECIFIC DELIVERY IN THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] ANALOGUES D'EPOTHILONE PERMETTANT L'ADMINISTRATION SPECIFIQUE D'UN SITE DANS LE TRAITEMENT DE MALADIES PROLIFERATIVES
  申请人：SCHERING AG

  公开号：WO2004050089A1

  公开（公告）日：2004-06-17

  Conjugates of epothilones and epothilone derivatives (as effectors) with suitable saccharides or saccharide derivatives (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compounds that are produced are conjugated to the effectors. The pharmaceutical use of the conjugates for treating proliferative or angiogenesis-associated processes is described.

  本文描述了用适当的糖或糖衍生物（作为识别单元）与紫杉醇类和紫杉醇衍生物（作为效应物）的共轭体。它们的生产是通过将识别单元与适当的连接剂反应，然后将产生的化合物与效应物共轭。本文还描述了共轭体在治疗增殖或血管生成相关过程中的药物用途。
• METHODS, KITS, AND COMPOUNDS FOR DETERMINING RESPONSIVENESS TO TREATMENT OF A PATHOLOGICAL DISORDER BY EPOTHILONES
  申请人：Hoffmann Jens

  公开号：US20090076098A1

  公开（公告）日：2009-03-19

  The invention provides methods, kits and compounds for determining the potential responsiveness of a subject suffering from a pathological disorder, including non-small cell lung cancer (NSCLC), to treatment with an epothilone by analyzing the gene expression profile and/or certain molecular markers in a sample obtained from said subject. The invention further relates to methods, compounds and uses of said compounds for treating subjects suffering from said pathologic disorder, optionally in combination with other therapeutic agents. Also provided are genes and/or proteins encoded by them whose expression level have been determined to differ between epothilone responders and epothilone non-responders.

  该发明提供了用于确定患有病理性疾病（包括非小细胞肺癌（NSCLC））的受试者对依托泊苷治疗的潜在反应性的方法、试剂盒和化合物，包括通过分析从该受试者获得的样本中的基因表达谱和/或某些分子标记来进行。该发明还涉及用于治疗患有该病理性疾病的受试者的方法、化合物和使用该化合物，可选择与其他治疗剂联合使用。还提供了由它们编码的基因和/或蛋白质，其表达水平已确定在依托泊苷反应者和依托泊苷非反应者之间存在差异。
• Effector conjugates, methods for their preparation and their pharmaceutical use
  申请人：——

  公开号：US20040167083A1

  公开（公告）日：2004-08-26

  Conjugates of epothilones and epothilone derivatives (as effectors) with suitable saccharides or saccharide derivatives (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compounds that are produced are conjugated to the effectors. The pharmaceutical use of the conjugates for treating proliferative or angiogenesis-associated processes is described.

  描述了具有适当的糖或糖衍生物（作为识别单元）的紫杉醇和紫杉醇衍生物（作为效应物）的共轭物。它们的制备是通过将识别单元与适当的连接剂反应，然后将产生的化合物与效应物共轭。描述了共轭物在治疗增殖或血管生成相关过程方面的药物应用。
• New effector conjugates, methods for their preparation and their pharmaceutical use
  申请人：Bosslet Klaus

  公开号：US20060276413A1

  公开（公告）日：2006-12-07

  Conjugates of epothilones and epothilone derivatives (as effectors) with suitable saccharides or saccharide derivatives (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compounds that are produced are conjugated to the effectors. The pharmaceutical use of the conjugates for treating proliferative or angiogenesis-associated processes is described.

  本文描述了与适当的糖或糖衍生物（作为识别单元）结合的依泊单酮及其衍生物的共轭物（作为效应物）。它们的生产是通过将识别单元与适当的连接剂反应，然后将产生的化合物与效应物结合而完成的。本文还描述了这些共轭物在治疗增殖或血管生成相关过程中的药物用途。